Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
This study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (<i>n</i> = 13) with cancer who had been administered olanzapine as an a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/7/9/140 |
| _version_ | 1797553490765021184 |
|---|---|
| author | So Rae Lee Su Min Kim Min Young Oh Jae Min Lee |
| author_facet | So Rae Lee Su Min Kim Min Young Oh Jae Min Lee |
| author_sort | So Rae Lee |
| collection | DOAJ |
| description | This study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (<i>n</i> = 13) with cancer who had been administered olanzapine as an anti-emetic drug (AED) during a high and moderate emetogenic chemotherapy block from January 2018 to March 2020. Patients were administered other prophylactic AEDs according to practice guidelines. The mean age of the patients was 14.1 ± 5.5 years. The total number of chemotherapy cycles was 41. Twenty-one (51.2%) chemotherapy blocks were high emetogenic chemotherapy and 20 (48.8%) blocks were moderate emetogenic chemotherapy. Olanzapine was used for prophylaxis in 20 (48.8%) blocks of chemotherapy and rescue in 21 (51.2%). Of the 41 cycles, a complete response to olanzapine was achieved in 31 (75.6%), partial response in 6 (14.6%), and no response in 4 (9.8%). The mean dose was 0.07 ± 0.04 mg/kg/dose and 2.50 ± 1.37 mg/m<sup>2</sup>/dose. Adverse effects included somnolence, hyperglycemia, fatigue, and disturbed sleep. Our findings indicate that olanzapine was effective and safe for treating chemotherapy-induced nausea and vomiting in children. A prospective controlled study is needed to confirm these findings. |
| first_indexed | 2024-03-10T16:17:12Z |
| format | Article |
| id | doaj.art-097002b3f560439685d934952e63b73a |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-10T16:17:12Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-097002b3f560439685d934952e63b73a2023-11-20T13:58:01ZengMDPI AGChildren2227-90672020-09-017914010.3390/children7090140Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in ChildrenSo Rae Lee0Su Min Kim1Min Young Oh2Jae Min Lee3Department of Medicine, College of Medicine, Yeungnam University, Daegu 42415, KoreaDepartment of Medicine, College of Medicine, Yeungnam University, Daegu 42415, KoreaDepartment of Medicine, College of Medicine, Yeungnam University, Daegu 42415, KoreaDepartment of Pediatrics, College of Medicine, Yeungnam University, Daegu 42415, KoreaThis study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (<i>n</i> = 13) with cancer who had been administered olanzapine as an anti-emetic drug (AED) during a high and moderate emetogenic chemotherapy block from January 2018 to March 2020. Patients were administered other prophylactic AEDs according to practice guidelines. The mean age of the patients was 14.1 ± 5.5 years. The total number of chemotherapy cycles was 41. Twenty-one (51.2%) chemotherapy blocks were high emetogenic chemotherapy and 20 (48.8%) blocks were moderate emetogenic chemotherapy. Olanzapine was used for prophylaxis in 20 (48.8%) blocks of chemotherapy and rescue in 21 (51.2%). Of the 41 cycles, a complete response to olanzapine was achieved in 31 (75.6%), partial response in 6 (14.6%), and no response in 4 (9.8%). The mean dose was 0.07 ± 0.04 mg/kg/dose and 2.50 ± 1.37 mg/m<sup>2</sup>/dose. Adverse effects included somnolence, hyperglycemia, fatigue, and disturbed sleep. Our findings indicate that olanzapine was effective and safe for treating chemotherapy-induced nausea and vomiting in children. A prospective controlled study is needed to confirm these findings.https://www.mdpi.com/2227-9067/7/9/140adolescentantiemeticschildhood cancerchemotherapy-induced nausea and vomitingolanzapine |
| spellingShingle | So Rae Lee Su Min Kim Min Young Oh Jae Min Lee Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children Children adolescent antiemetics childhood cancer chemotherapy-induced nausea and vomiting olanzapine |
| title | Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children |
| title_full | Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children |
| title_fullStr | Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children |
| title_full_unstemmed | Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children |
| title_short | Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children |
| title_sort | efficacy of olanzapine for high and moderate emetogenic chemotherapy in children |
| topic | adolescent antiemetics childhood cancer chemotherapy-induced nausea and vomiting olanzapine |
| url | https://www.mdpi.com/2227-9067/7/9/140 |
| work_keys_str_mv | AT soraelee efficacyofolanzapineforhighandmoderateemetogenicchemotherapyinchildren AT suminkim efficacyofolanzapineforhighandmoderateemetogenicchemotherapyinchildren AT minyoungoh efficacyofolanzapineforhighandmoderateemetogenicchemotherapyinchildren AT jaeminlee efficacyofolanzapineforhighandmoderateemetogenicchemotherapyinchildren |